Transplant patients get extra weapon

Organ transplant patients now have a new weapon to help fight organ rejection during the critical first eight weeks following surgery. The new drug Zenapax blocks immune cells from attacking new organs during the first eight weeks after a transplant. Recently approved by the U.S. Food and Drug Administration, Zenapax is a monoclonal antibody administered with standard anti-rejection drugs such as cyclosporine and causes no additional side effects, according to Nutley, NJ-based Hoffman-La Roche, manufacturer of the drug. Marketed under as Zenapax, the drug’s generic name is daclizumab.

Whose Ethics? Which Medicine? The Tacit and Explicit Development of a Medical Ethic. April 17-18, 1998, Youngstown, OH. Sponsored by Youngstown State University and the Annual Spring Regional Meeting of the Society for Health and Human Values. Contact: Jody Chidester, Center for Medical Ethics, 3708 Fifth Ave., Suite 300, Pittsburgh, PA 15213.

A Conference on Health Care — Public or Private, including the Jewish, Christian, and Islamic Perspectives. May 13, 1998, Pittsburgh. Sponsored by Duquesne University, St. Francis Medical Center, and Mercy Health System. Contact: Christine Sedlack, The Center for Critical Care Medicine, St. Francis Medical Center, 400 45th St., Pittsburgh, PA 15201. Telephone: (412) 622-6191.

Families on the Frontier of Dying. May 21-22, 1998, The Ritz Carlton, Philadelphia. Sponsored by University of Pennsylvania Health System Center for Bioethics. Contact: Toni Rouse or Sally Nunn, Center for Bioethics, University of Pennsylvania Health System, 3401 Market St., Suite 320, Philadelphia, PA 19104-3308. Tele-phone: (215) 898-7136. Fax: (215) 573-3036. E-mail: and